{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T06:56:52Z","timestamp":1794121012434,"version":"4.8.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institut National de la recherch\u00e9 m\u00e9dicale (Inserm U1245), Rouen University and the Normandy Region"},{"DOI":"10.13039\/100008722","name":"Universitat de Girona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008722","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Discovered in 1989, pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with strong neuroprotective properties, as shown in various neurodegenerative preclinical models of Parkinson, Alzheimer, or Huntington diseases. PACAP neuroprotection has also been reported in animal models of cerebral ischemia and traumatic brain injury. The neuroprotective effect of PACAP occurs through its capacity to modulate most of the multiphasic aspects of neuronal diseases, such as oxidative stress, neuronal cell death, and inflammation. However, more than three decades after its discovery, and although PACAP neurotrophic and neuroprotective activities have now been largely documented, its clinical use is still awaited. Thus, the aim of this manuscript is to discuss the main reasons which limit the use of PACAP as a therapeutic agent for the treatment of neuronal diseases. To achieve this objective, an opinion survey has been conducted among experts in the field of PACAP, and a bibliographic investigation was carried out.<\/jats:p>","DOI":"10.1007\/s12031-025-02366-z","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T03:03:58Z","timestamp":1750475038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["More Than Three Decades After Discovery of the Neuroprotective Effect of PACAP, What Is Still Preventing Its Clinical Use?"],"prefix":"10.1007","volume":"75","author":[{"given":"Asma","family":"Cherait","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Xifr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora","family":"Reglodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"2366_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.4103\/ijp.IJP_384_20","volume":"54","author":"KV Abhangi","year":"2022","unstructured":"Abhangi KV, Patel J (2022) Neuroprotective effects of linagliptin in a rotenone-induced rat model of Parkinson\u2019s disease. Indian J Pharmacol 54:46\u201350. https:\/\/doi.org\/10.4103\/ijp.IJP_384_20","journal-title":"Indian J Pharmacol"},{"key":"2366_CR2","doi-asserted-by":"publisher","first-page":"717490","DOI":"10.3389\/fnins.2021.717490","volume":"15","author":"Y Ago","year":"2021","unstructured":"Ago Y, Asano S, Hashimoto H, Waschek JA (2021) Probing the VIPR2 microduplication linkage to schizophrenia in animal and cellular models. Front Neurosci 15:717490. https:\/\/doi.org\/10.3389\/fnins.2021.717490","journal-title":"Front Neurosci"},{"key":"2366_CR3","doi-asserted-by":"publisher","first-page":"114339","DOI":"10.1016\/j.expneurol.2023.114339","volume":"362","author":"Y Ago","year":"2023","unstructured":"Ago Y, Van C, Condro MC, Hrncir H, Diep AL, Rajbhandari AK, Fanselow MS, Hashimoto H, MacKenzie-Graham AJ, Waschek JA (2023) Overexpression of VIPR2 in mice results in microencephaly with paradoxical increased white matter volume. Exp Neurol 362:114339. https:\/\/doi.org\/10.1016\/j.expneurol.2023.114339","journal-title":"Exp Neurol"},{"issue":"6","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.tips.2018.02.011","volume":"39","author":"M Alhouayek","year":"2018","unstructured":"Alhouayek M, Masquelier J, Muccioli GG (2018) Lysophosphatidylinositols, from Cell membrane constituents to GPR55 ligands. Trends Pharmacol Sci 39(6):586\u2013604. https:\/\/doi.org\/10.1016\/j.tips.2018.02.011","journal-title":"Trends Pharmacol Sci"},{"key":"2366_CR5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s43441-024-00637-2","volume":"58","author":"H Aljohani","year":"2024","unstructured":"Aljohani H, Alrubaish FS, Alghamdi WM, Al-Harbi F (2024) Safety of linagliptin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Ther Innov Regul Sci 58:622\u2013633. https:\/\/doi.org\/10.1007\/s43441-024-00637-2","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"2366_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s10194-018-0861-3","volume":"19","author":"FM Amin","year":"2018","unstructured":"Amin FM, Schytz HW (2018) Transport of the pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier: implications for migraine. J Headache Pain 19(1):35. https:\/\/doi.org\/10.1186\/s10194-018-0861-3","journal-title":"J Headache Pain"},{"issue":"2","key":"2366_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0333102411431333","volume":"32","author":"FM Amin","year":"2012","unstructured":"Amin FM, Asghar MS, Guo S, Hougaard A, Hansen AE, Schytz HW, van der Geest RJ, de Koning PJ, Larsson HB, Olesen J, Ashina M (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32(2):140\u2013149. https:\/\/doi.org\/10.1177\/0333102411431333","journal-title":"Cephalalgia"},{"key":"2366_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/brain\/awt369","volume":"137","author":"FM Amin","year":"2014","unstructured":"Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, de Koning PJ, Andersen MR, Larsson HB, Fahrenkrug J, Olesen J, Ashina M (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137:779\u2013794. https:\/\/doi.org\/10.1093\/brain\/awt369","journal-title":"Brain"},{"key":"2366_CR9","doi-asserted-by":"publisher","first-page":"818003","DOI":"10.3389\/fddsv.2021.818003","volume":"1","author":"CR Apostol","year":"2022","unstructured":"Apostol CR, Bernard K, Tanguturi P, Molnar G, Bartlett MJ, Szab\u00f2 L, Liu C, Ortiz JB, Saber M, Giordano KR, Green TRF, Melvin J, Morrison HW, Madhavan L, Rowe RK, Streicher JM, Heien ML, Falk T, Polt R (2022) Design and synthesis of brain penetrant glycopeptide analogues of PACAP with neuroprotective potential for traumatic brain injury and parkinsonism. Front Drug Discov 1:818003. https:\/\/doi.org\/10.3389\/fddsv.2021.818003","journal-title":"Front Drug Discov"},{"issue":"8","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/ph16081065","volume":"16","author":"HH Arab","year":"2023","unstructured":"Arab HH, Eid AH, Alsufyani SE, Ashour AM, El-Sheikh AAK, Darwish HW, Georgy GS (2023) Neuroprotective impact of linagliptin against cadmium-induced cognitive impairment and neuropathological aberrations: targeting SIRT1\/Nrf2 axis, apoptosis, and autophagy. Pharmaceuticals 16(8):1065. https:\/\/doi.org\/10.3390\/ph16081065","journal-title":"Pharmaceuticals"},{"key":"2366_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0167-0115(92)90621-z","volume":"37","author":"A Arimura","year":"1992","unstructured":"Arimura A (1992) Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept 37:287\u2013303. https:\/\/doi.org\/10.1016\/0167-0115(92)90621-z","journal-title":"Regul Pept"},{"issue":"9","key":"2366_CR12","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.peptides.2007.06.006","volume":"28","author":"A Arimura","year":"2007","unstructured":"Arimura A (2007) PACAP: the road to discovery. Peptides 28(9):1617\u20131619. https:\/\/doi.org\/10.1016\/j.peptides.2007.06.006","journal-title":"Peptides"},{"key":"2366_CR13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1006\/frne.1995.1003","volume":"16","author":"A Arimura","year":"1995","unstructured":"Arimura A, Shioda S (1995) Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction. Front Neuroendocrinol 16:1003. https:\/\/doi.org\/10.1006\/frne.1995.1003","journal-title":"Front Neuroendocrinol"},{"key":"2366_CR14","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1210\/endo-129-5-2787","volume":"129","author":"A Arimura","year":"1991","unstructured":"Arimura A, Somogyv\u00e1ri-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129:2787\u20132789. https:\/\/doi.org\/10.1210\/endo-129-5-2787","journal-title":"Endocrinology"},{"key":"2366_CR15","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"M Ashina","year":"2020","unstructured":"Ashina M (2020) Migraine. N Engl J Med 383:1866\u20131876. https:\/\/doi.org\/10.1056\/NEJMra1915327","journal-title":"N Engl J Med"},{"issue":"1","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0333102420970889","volume":"41","author":"M Ashina","year":"2021","unstructured":"Ashina M, Dole\u017eil D, Bonner JH, Zhou L, Klatt J, Picard H, Mikol DD (2021) A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia 41(1):33\u201344. https:\/\/doi.org\/10.1177\/0333102420970889","journal-title":"Cephalalgia"},{"issue":"11","key":"2366_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41582-024-01011-4","volume":"20","author":"H Ashina","year":"2024","unstructured":"Ashina H, Christensen RH, Hay DL, Pradhan AA, Hoffmann J, Reglodi D, Russo AF, Ashina M (2024) Pituitary adenylate cyclase-activating polypeptide signalling as a therapeutic target in migraine. Nat Rev Neurol 20(11):660\u2013670. https:\/\/doi.org\/10.1038\/s41582-024-01011-4","journal-title":"Nat Rev Neurol"},{"key":"2366_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/j.1749-6632.1996.tb17489.x","volume":"805","author":"WA Banks","year":"1996","unstructured":"Banks WA, Uchida D, Arimura A, Somogyv\u00e1ri-Vigh A, Shioda S (1996) Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann N Y Acad Sci 805:270\u2013279. https:\/\/doi.org\/10.1111\/j.1749-6632.1996.tb17489.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2366_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1006\/exnr.1998.6786","volume":"151","author":"WA Banks","year":"1998","unstructured":"Banks WA, Kastin AJ, Arimura A (1998) Effect of spinal cord injury on the permeability of the blood-brain and blood-spinal cord barriers to the neurotropin PACAP. Exp Neurol 151(1):116\u2013123. https:\/\/doi.org\/10.1006\/exnr.1998.6786","journal-title":"Exp Neurol"},{"key":"2366_CR20","doi-asserted-by":"publisher","unstructured":"Banks WA (2016) Transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier: consequences for disease states and therapeutic effects. In: Reglodi D, Tamas A (eds) Pituitary Adenylate Cyclase Activating Polypeptide \u2014 PACAP, Current Topics in Neurotoxicity, Springer: Cham, Switzerland, Volume 11. https:\/\/doi.org\/10.1007\/978-3-319-35135-3_25","DOI":"10.1007\/978-3-319-35135-3_25"},{"key":"2366_CR21","doi-asserted-by":"publisher","first-page":"932099","DOI":"10.3389\/fphys.2022.932099","volume":"13","author":"T Barra","year":"2022","unstructured":"Barra T, Falanga A, Bellavita R, Laforgia V, Prisco M, Galdiero S, Valiante S (2022) a gH625-liposomes deliver PACAP through a dynamic in vitro model of the blood-brain barrier. Front Physiol 13:932099. https:\/\/doi.org\/10.3389\/fphys.2022.932099","journal-title":"Front Physiol"},{"issue":"10","key":"2366_CR22","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.3390\/biomedicines10102644b","volume":"10","author":"T Barra","year":"2022","unstructured":"Barra T, Falanga A, Bellavita R, Pisano J, Laforgia V, Prisco M, Galdiero S, Valiante S (2022) b Neuroprotective effects of gH625-lipoPACAP in an in vitro fluid dynamic model of Parkinson\u2019s disease. Biomedicines 10(10):2644. https:\/\/doi.org\/10.3390\/biomedicines10102644b","journal-title":"Biomedicines"},{"key":"2366_CR23","doi-asserted-by":"publisher","first-page":"137883","DOI":"10.1016\/j.neulet.2024.137883","volume":"836","author":"K Bernard","year":"2024","unstructured":"Bernard K, Dickson D, Anglin BL, Leandro Heien M, Polt R, Morrison HW, Falk T (2024) PACAP glycosides promote cell outgrowth in vitro and reduce infarct size after stroke in a preclinical model. Neurosci Lett 836:137883. https:\/\/doi.org\/10.1016\/j.neulet.2024.137883","journal-title":"Neurosci Lett"},{"key":"2366_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.regpep.2006.12.010","volume":"140","author":"S Birk","year":"2007","unstructured":"Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, Olesen J (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140:185\u2013191","journal-title":"Regul Pept"},{"issue":"4","key":"2366_CR25","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1007\/s13346-021-01086-2","volume":"12","author":"ML Borrajo","year":"2022","unstructured":"Borrajo ML, Alonso MJ (2022) Using nanotechnology to deliver biomolecules from nose to brain - peptides, proteins, monoclonal antibodies and RNA. Drug Deliv Transl Res 12(4):862\u2013880. https:\/\/doi.org\/10.1007\/s13346-021-01086-2","journal-title":"Drug Deliv Transl Res"},{"key":"2366_CR26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.peptides.2008.01.022","volume":"29","author":"S Bourgault","year":"2008","unstructured":"Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H, Fournier A (2008) Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29:919\u2013932. https:\/\/doi.org\/10.1016\/j.peptides.2008.01.022","journal-title":"Peptides"},{"key":"2366_CR27","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.2174\/092986709789712899","volume":"16","author":"S Bourgault","year":"2009","unstructured":"Bourgault S, Vaudry D, Dejda A, Doan ND, Vaudry H, Fournier A (2009a) Pituitary adenylate cyclase-activating polypeptide: focus on structure-activity relationships of a neuroprotective Peptide. Curr Med Chem 16:4462\u20134480. https:\/\/doi.org\/10.2174\/092986709789712899","journal-title":"Curr Med Chem"},{"issue":"10","key":"2366_CR28","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1021\/jm900291j","volume":"52","author":"S Bourgault","year":"2009","unstructured":"Bourgault S, Vaudry D, Segalas-Milazzo I, Guilhaudis L, Couvineau A, Laburthe M, Vaudry H, Fournier A (2009) b Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem 52(10):3308\u20133316","journal-title":"J Med Chem"},{"issue":"10","key":"2366_CR29","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.2174\/138161211795589337","volume":"17","author":"S Bourgault","year":"2011","unstructured":"Bourgault S, Chatenet D, Wurtz O, Doan ND, Leprince J, Vaudry H, Fournier A, Vaudry D (2011) Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug. Curr Pharm Des 17(10):1002\u201324. https:\/\/doi.org\/10.2174\/138161211795589337","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2366_CR30","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1161\/STROKEAHA.114.006864","volume":"46","author":"C Brifault","year":"2015","unstructured":"Brifault C, Gras M, Liot D, May V, Vaudry D, Wurtz O (2015) Delayed pituitary adenylate cyclase-activating polypeptide delivery after brain stroke improves functional recovery by inducing m2 microglia\/macrophage polarization. Stroke 46(2):520\u2013528. https:\/\/doi.org\/10.1161\/STROKEAHA.114.006864","journal-title":"Stroke"},{"key":"2366_CR31","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1038\/npp.2014.61","volume":"39","author":"V Brown","year":"2014","unstructured":"Brown V, Liu F (2014) Intranasal delivery of a peptide with antidepressant-like effect. Neuropsychopharmacol 39:2131\u20132141. https:\/\/doi.org\/10.1038\/npp.2014.61","journal-title":"Neuropsychopharmacol"},{"key":"2366_CR32","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1007\/s12035-018-0972-5","volume":"55","author":"N Cabezas-Llobet","year":"2018","unstructured":"Cabezas-Llobet N, Vidal-Sancho L, Masana M, Fournier A, Alberch J, Vaudry D, Xifr\u00f3 X (2018) Pituitary adenylate cyclase-activating polypeptide (PACAP) enhances hippocampal synaptic plasticity and improves memory performance in Huntington\u2019s disease. Mol Neurobiol 55:8263\u20138277. https:\/\/doi.org\/10.1007\/s12035-018-0972-5","journal-title":"Mol Neurobiol"},{"issue":"2","key":"2366_CR33","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.05.009","volume":"144","author":"P Calias","year":"2014","unstructured":"Calias P, Banks WA, Begley D, Scarpa M, Dickson P (2014) Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. Pharmacol Ther 144(2):114\u2013122. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.05.009","journal-title":"Pharmacol Ther"},{"key":"2366_CR34","doi-asserted-by":"publisher","first-page":"585082","DOI":"10.3389\/fendo.2020.585082","volume":"11","author":"A Cherait","year":"2021","unstructured":"Cherait A, Maucotel J, Lefranc B, Leprince J, Vaudry D (2021) Intranasal administration of PACAP is an efficient delivery route to reduce infarct volume and promote functional recovery after transient and permanent middle cerebral artery occlusion. Front Endocrinol 11:585082. https:\/\/doi.org\/10.3389\/fendo.2020.585082","journal-title":"Front Endocrinol"},{"issue":"8","key":"2366_CR35","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.3390\/pharmaceutics15082032","volume":"15","author":"A Cherait","year":"2023","unstructured":"Cherait A, Banks WA, Vaudry D (2023) The potential of the nose-to-brain delivery of PACAP for the treatment of neuronal disease. Pharmaceutics 15(8):2032. https:\/\/doi.org\/10.3390\/pharmaceutics15082032","journal-title":"Pharmaceutics"},{"key":"2366_CR36","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c10183","author":"CL Chou","year":"2024","unstructured":"Chou CL, Lin CT, Kao CT, Lin CC (2024) A novel rational PROTACs design and validation via AI-driven drug design approach. ACS Omega. https:\/\/doi.org\/10.1021\/acsomega.3c10183","journal-title":"ACS Omega"},{"issue":"2","key":"2366_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.npep.2012.08.008","volume":"47","author":"V Darsalia","year":"2013","unstructured":"Darsalia V, Mansouri S, Wolbert P, Barde S, Sj\u00f6holm A, Patrone C (2013) The specific VPAC2 agonist Bay 55\u20139837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats. Neuropeptides 47(2):133\u2013137. https:\/\/doi.org\/10.1016\/j.npep.2012.08.008","journal-title":"Neuropeptides"},{"issue":"2","key":"2366_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12640-009-9091-4","volume":"17","author":"J Deguil","year":"2010","unstructured":"Deguil J, Chavant F, Lafay-Chebassier C, P\u00e9rault-Pochat MC, Fauconneau B, Pain S (2010) Neuroprotective effect of PACAP on translational control alteration and cognitive decline in MPTP parkinsonian mice. Neurotox Res 17(2):142\u2013155. https:\/\/doi.org\/10.1007\/s12640-009-9091-4","journal-title":"Neurotox Res"},{"issue":"4","key":"2366_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.biochi.2010.12.010","volume":"93","author":"A Dejda","year":"2011","unstructured":"Dejda A, Bourgault S, Doan ND, L\u00e9tourneau M, Couvineau A, Vaudry H, Vaudry D, Fournier A (2011a) Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP. Biochimie 93(4):669\u2013677. https:\/\/doi.org\/10.1016\/j.biochi.2010.12.010","journal-title":"Biochimie"},{"issue":"6","key":"2366_CR40","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.peptides.2011.04.003","volume":"32","author":"A Dejda","year":"2011","unstructured":"Dejda A, Seaborn T, Bourgault S, Touzani O, Fournier A, Vaudry H, Vaudry D (2011b) PACAP and a novel stable analog protect rat brain from ischemia: insight into the mechanisms of action. Peptides 32(6):1207\u20131216. https:\/\/doi.org\/10.1016\/j.peptides.2011.04.003","journal-title":"Peptides"},{"key":"2366_CR41","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3390\/jcm8091488","volume":"8","author":"V Denes","year":"2019","unstructured":"Denes V, Geck P, Mester A, Gabriel R (2019) Pituitary adenylate cyclase-activating polypeptide: 30 years in research spotlight and 600 million years in service. J Clin Med 8:1488. https:\/\/doi.org\/10.3390\/jcm8091488","journal-title":"J Clin Med"},{"issue":"4","key":"2366_CR42","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/jps.21924","volume":"99","author":"SV Dhuria","year":"2010","unstructured":"Dhuria SV, Hanson LR, Frey WH (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654\u20131673. https:\/\/doi.org\/10.1002\/jps.21924","journal-title":"J Pharm Sci"},{"issue":"8","key":"2366_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1365-2362.2007.01832.x","volume":"37","author":"D Doberer","year":"2007","unstructured":"Doberer D, Gschwandtner M, Mosgoeller W, Bieglmayer C, Heinzl H, Petkov V (2007) Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects. Eur J Clin Invest 37(8):665\u2013672. https:\/\/doi.org\/10.1111\/j.1365-2362.2007.01832.x","journal-title":"Eur J Clin Invest"},{"key":"2366_CR44","unstructured":"Donahue RJ (2016) The role of pituitary adenylate cyclase-activating polypeptide (PACAP) in the neurobiology of stress-related behaviors. Doctoral dissertation, 2016, Harvard University, Graduate School of Arts & Sciences. http:\/\/nrs.harvard.edu\/urn-3:HUL.InstRepos:33493397. Consulted 30\/10\/2023"},{"key":"2366_CR45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","volume":"19","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Tajti J, Szal\u00e1rdy L, V\u00e9csei L (2018) PACAP and its role in primary headaches. J Headache Pain 19:21. https:\/\/doi.org\/10.1186\/s10194-018-0852-4","journal-title":"J Headache Pain"},{"issue":"13","key":"2366_CR46","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.3390\/molecules27134020","volume":"27","author":"LE Elend","year":"2022","unstructured":"Elend LE, Jacobsen L, Cofala T, Prellberg J, Teusch T, Kramer O, Solov\u2019yov IA (2022) Design of SARS-CoV-2 main protease inhibitors using artificial intelligence and molecular dynamic simulations. Molecules 27(13):4020. https:\/\/doi.org\/10.3390\/molecules27134020","journal-title":"Molecules"},{"key":"2366_CR47","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1113\/jphysiol.1969.sp008937","volume":"204","author":"M Fabian","year":"1969","unstructured":"Fabian M, Forsling ML, Jones JJ, Pryor JS (1969) The clearance and antidiuretic potency of neurohypophysial hormones in man, and their plasma binding and stability. J Physiol 204:653\u2013668. https:\/\/doi.org\/10.1113\/jphysiol.1969.sp008937","journal-title":"J Physiol"},{"issue":"4","key":"2366_CR48","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1007\/s13311-020-00925-3","volume":"17","author":"Y Fang","year":"2020","unstructured":"Fang Y, Shi H, Ren R, Huang L, Okada T, Lenahan C, Gamdzyk M, Travis ZD, Lu Q, Tang L, Huang Y, Zhou K, Tang J, Zhang J, Zhang JH (2020) Pituitary adenylate cyclase-activating polypeptide attenuates brain edema by protecting blood-brain barrier and glymphatic system after subarachnoid hemorrhage in rats. Neurotherapeutics 17(4):1954\u20131972. https:\/\/doi.org\/10.1007\/s13311-020-00925-3","journal-title":"Neurotherapeutics"},{"issue":"1","key":"2366_CR49","doi-asserted-by":"publisher","first-page":"H214","DOI":"10.1152\/ajpheart.00662.2010","volume":"300","author":"MM Farnham","year":"2011","unstructured":"Farnham MM, Inglott MA, Pilowsky PM (2011) Intrathecal PACAP-38 causes increases in sympathetic nerve activity and heart rate but not blood pressure in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 300(1):H214\u2013H222. https:\/\/doi.org\/10.1152\/ajpheart.00662.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2366_CR50","doi-asserted-by":"publisher","first-page":"11843","DOI":"10.3390\/ijms241411843","volume":"24","author":"M Feher","year":"2023","unstructured":"Feher M, M\u00e1rton Z, Szab\u00f3 \u00c1, Kocsa J, Kormos V, Hunyady \u00c1, Kov\u00e1cs L\u00c1, Ujv\u00e1ri B, Berta G, Farkas J, F\u00fcredi N, Gaszner T, Pytel B, Regl\u0151di D, Gaszner B (2023) Downregulation of PACAP and the PAC1 receptor in the basal ganglia, substantia nigra and centrally projecting edinger-Westphal nucleus in the rotenone model of Parkinson\u2019s disease. Int J Mol Sci 24:11843. https:\/\/doi.org\/10.3390\/ijms241411843","journal-title":"Int J Mol Sci"},{"key":"2366_CR51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1113\/jphysiol.2003.053835","volume":"554","author":"L Fizanne","year":"2004","unstructured":"Fizanne L, Sigaudo-Roussel D, Saumet JL, Fromy B (2004) Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents. J Physiol 554:519\u2013528. https:\/\/doi.org\/10.1113\/jphysiol.2003.053835","journal-title":"J Physiol"},{"key":"2366_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cell.2019.10.010","volume":"179","author":"SR Foster","year":"2019","unstructured":"Foster SR, Hauser AS, Vedel L, Strachan RT, Huang XP, Gavin AC, Shah SD, Nayak AP, Haugaard-Kedstr\u00f6m LM, Penn RB, Roth BL, Br\u00e4uner-Osborne H, Gloriam DE (2019) Discovery of human signaling systems: pairing peptides to g protein-coupled receptors. Cell 179:895\u2013908. https:\/\/doi.org\/10.1016\/j.cell.2019.10.010","journal-title":"Cell"},{"key":"2366_CR53","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.3389\/fnins.2019.01031","volume":"13","author":"R Gabriel","year":"2019","unstructured":"Gabriel R, P\u00f6sty\u00e9ni E, D\u00e9nes V (2019) Neuroprotective potential of pituitary adenylate cyclase activating polypeptide in retinal degenerations of metabolic origin. Front Neurosci 13:1031. https:\/\/doi.org\/10.3389\/fnins.2019.01031","journal-title":"Front Neurosci"},{"key":"2366_CR54","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0333102419864507","volume":"40","author":"H Ghanizada","year":"2020","unstructured":"Ghanizada H, Al-Karagholi MA, Arngrim N, Olesen J, Ashina M (2020) PACAP27 induces migraine-like attacks in migraine patients. Cephalalgia 40:57\u201367. https:\/\/doi.org\/10.1177\/0333102419864507","journal-title":"Cephalalgia"},{"key":"2366_CR55","doi-asserted-by":"publisher","unstructured":"Gozes I (2016) PACAP, VIP, and ADNP: autism and schizophrenia. In: Reglodi D, Tamas A (eds) Pituitary adenylate cyclase activating polypeptide \u2014 PACAP, Current Topics in Neurotoxicity, Springer Cham, Switzerland, Volume 11. https:\/\/doi.org\/10.1007\/978-3-319-35135-3_46","DOI":"10.1007\/978-3-319-35135-3_46"},{"issue":"6","key":"2366_CR56","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.peptides.2005.11.010","volume":"27","author":"BD Green","year":"2006","unstructured":"Green BD, Irwin N, Flatt PR (2006) Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential. Peptides 27(6):1349\u20131358. https:\/\/doi.org\/10.1016\/j.peptides.2005.11.010","journal-title":"Peptides"},{"issue":"9","key":"2366_CR57","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1007\/s12035-021-02381-2","volume":"58","author":"X Guo","year":"2021","unstructured":"Guo X, Tian Y, Yang Y, Li S, Guo L, Shi J (2021) Pituitary adenylate cyclase-activating polypeptide protects against cognitive impairment caused by chronic cerebral hypoperfusion. Mol Neurobiol 58(9):4309\u20134322. https:\/\/doi.org\/10.1007\/s12035-021-02381-2","journal-title":"Mol Neurobiol"},{"issue":"11","key":"2366_CR58","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1038\/sj.mp.4001982","volume":"12","author":"R Hashimoto","year":"2007","unstructured":"Hashimoto R, Hashimoto H, Shintani N, Chiba S, Hattori S, Okada T, Nakajima M, Tanaka K, Kawagishi N, Nemoto K, Mori T, Ohnishi T, Noguchi H, Hori H, Suzuki T, Iwata N, Ozaki N, Nakabayashi T, Saitoh O, Kosuga A, Tatsumi M, Kamijima K, Weinberger DR, Kunugi H, Baba A (2007) Pituitary adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Psychiatry 12(11):1026\u201332. https:\/\/doi.org\/10.1038\/sj.mp.4001982","journal-title":"Mol Psychiatry"},{"issue":"3","key":"2366_CR59","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.neulet.2009.11.019","volume":"468","author":"R Hashimoto","year":"2010","unstructured":"Hashimoto R, Hashimoto H, Shintani N, Ohi K, Hori H, Saitoh O, Kosuga A, Tatsumi M, Iwata N, Ozaki N, Kamijima K, Baba A, Takeda M, Kunugi H (2010) Possible association between the pituitary adenylate cyclase-activating polypeptide (PACAP) gene and major depressive disorder. Neurosci Lett 468(3):300\u2013302. https:\/\/doi.org\/10.1016\/j.neulet.2009.11.019","journal-title":"Neurosci Lett"},{"issue":"2","key":"2366_CR60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1208\/s12249-011-9614-1","volume":"12","author":"JD Hoekman","year":"2011","unstructured":"Hoekman JD, Ho RJ (2011) Effects of localized hydrophilic mannitol and hydrophobic nelfinavir administration targeted to olfactory epithelium on brain distribution. AAPS PharmSciTech 12(2):534\u2013543. https:\/\/doi.org\/10.1208\/s12249-011-9614-1","journal-title":"AAPS PharmSciTech"},{"key":"2366_CR61","doi-asserted-by":"publisher","first-page":"9183","DOI":"10.1038\/s41598-019-45137-8","volume":"9","author":"G Iachetta","year":"2019","unstructured":"Iachetta G, Falanga A, Molino Y, Masse M, Jab\u00e8s F, Mechioukhi Y, Laforgia V, Khrestchatisky M, Galdiero S, Valiante S (2019) gH625-liposomes as tool for pituitary adenylate cyclase-activating polypeptide brain delivery. Sci Rep 9:9183. https:\/\/doi.org\/10.1038\/s41598-019-45137-8","journal-title":"Sci Rep"},{"issue":"2","key":"2366_CR62","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.neuroscience.2009.02.028","volume":"160","author":"V Jolivel","year":"2009","unstructured":"Jolivel V, Basille M, Aubert N, de Jouffrey S, Ancian P, Le Bigot JF, Noack P, Massonneau M, Fournier A, Vaudry H, Gonzalez BJ, Vaudry D (2009) Distribution and functional characterization of pituitary adenylate cyclase-activating polypeptide receptors in the brain of non-human primates. Neuroscience 160(2):434\u2013451. https:\/\/doi.org\/10.1016\/j.neuroscience.2009.02.028","journal-title":"Neuroscience"},{"issue":"12","key":"2366_CR63","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2174\/1381612033455206","volume":"9","author":"A Krishnadas","year":"2003","unstructured":"Krishnadas A, Ony\u00fcksel H, Rubinstein I (2003) Interactions of VIP, secretin and PACAP(1\u201338) with phospholipids: a biological paradox revisited. Curr Pharm des 9(12):1005\u20131012. https:\/\/doi.org\/10.2174\/1381612033455206","journal-title":"Curr Pharm des"},{"issue":"1","key":"2366_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-023-01569-2","volume":"24","author":"A Kuburas","year":"2023","unstructured":"Kuburas A, Russo AF (2023) Shared and independent roles of CGRP and PACAP in migraine pathophysiology. J Headache Pain 24(1):34. https:\/\/doi.org\/10.1186\/s10194-023-01569-2","journal-title":"J Headache Pain"},{"issue":"5","key":"2366_CR65","doi-asserted-by":"publisher","first-page":"e19682","DOI":"10.1371\/journal.pone.0019682","volume":"6","author":"S Kumar","year":"2011","unstructured":"Kumar S, Pioszak A, Zhang C, Swaminathan K, Xu HE (2011) Crystal structure of the PAC1R extracellular domain unifies a consensus fold for hormone recognition by class B G-protein coupled receptors. PLoS One 6(5):e19682. https:\/\/doi.org\/10.1371\/journal.pone.0019682","journal-title":"PLoS One"},{"key":"2366_CR66","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.bbr.2018.10.023","volume":"359","author":"MH Ladjimi","year":"2019","unstructured":"Ladjimi MH, Barbouche R, Ben Barka Z, Vaudry D, Lefranc B, Leprince J, Troadec JD, Ben Rhouma K, Sakly M, Tebourbi O, Save E (2019) Comparison of the effects of PACAP-38 and its analog, acetyl-[Ala15, Ala20] PACAP-38-propylamide, on spatial memory, post-learning BDNF expression and oxidative stress in rat. Behav Brain Res 359:247\u2013257. https:\/\/doi.org\/10.1016\/j.bbr.2018.10.023","journal-title":"Behav Brain Res"},{"key":"2366_CR67","doi-asserted-by":"publisher","first-page":"146858","DOI":"10.1016\/j.brainres.2020.146858","volume":"1739","author":"MH Ladjimi","year":"2020","unstructured":"Ladjimi MH, Barbouche R, Ben Rhouma K, Sakly M, Tebourbi O, Save E (2020) Effects of PACAP-38 and an analog, acetyl-[Ala15, Ala20] PACAP-38-propylamide, on memory consolidation in the detection of spatial novelty task in rats. Brain Res 1739:146858. https:\/\/doi.org\/10.1016\/j.brainres.2020.146858","journal-title":"Brain Res"},{"key":"2366_CR68","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.neuropharm.2015.05.014","volume":"108","author":"A Lamine","year":"2016","unstructured":"Lamine A, L\u00e9tourneau M, Doan ND, Maucotel J, Couvineau A, Vaudry H, Chatenet D, Vaudry D, Fournier A (2016) Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson\u2019s disease model. J Neuropharm 108:440\u2013450. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.05.014","journal-title":"J Neuropharm"},{"key":"2366_CR69","doi-asserted-by":"publisher","first-page":"129410","DOI":"10.1016\/j.bbagen.2019.08.003","volume":"1863","author":"A Lamine","year":"2019","unstructured":"Lamine A, Poujol de Molliens M, L\u00e9tourneau M, H\u00e9bert TE, Vaudry D, Fournier A, Chatenet D (2019) The amidated PACAP1-23 fragment is a potent reduced-size neuroprotective agent. Biochim Biophys Acta Gen Subj 1863:129410. https:\/\/doi.org\/10.1016\/j.bbagen.2019.08.003","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"2","key":"2366_CR70","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/biomedicines10020406","volume":"10","author":"I Langer","year":"2022","unstructured":"Langer I, Jeandriens J, Couvineau A, Sanmukh S, Latek D (2022) Signal transduction by VIP and PACAP receptors. Biomedicines 10(2):406. https:\/\/doi.org\/10.3390\/biomedicines10020406","journal-title":"Biomedicines"},{"key":"2366_CR71","doi-asserted-by":"publisher","first-page":"102919","DOI":"10.1016\/j.sbi.2024.102919","volume":"89","author":"A Lappala","year":"2024","unstructured":"Lappala A (2024) The next revolution in computational simulations: harnessing AI and quantum computing in molecular dynamics. Curr Opin Struct Biol 89:102919. https:\/\/doi.org\/10.1016\/j.sbi.2024.102919","journal-title":"Curr Opin Struct Biol"},{"key":"2366_CR72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1749-6632.2000.tb06954.x","volume":"921","author":"J Leceta","year":"2000","unstructured":"Leceta J, Gomariz RP, Martinez C, Abad C, Ganea D, Delgado M (2000) Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann NY Acad Sci 921:92\u2013102. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06954.x","journal-title":"Ann NY Acad Sci"},{"issue":"7","key":"2366_CR73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.5483\/bmbrep.2014.47.7.086","volume":"47","author":"EH Lee","year":"2014","unstructured":"Lee EH, Seo SR (2014) Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. BMB Rep 47(7):369\u2013375. https:\/\/doi.org\/10.5483\/bmbrep.2014.47.7.086","journal-title":"BMB Rep"},{"key":"2366_CR74","unstructured":"Lee-Gosselin L (2017) Analyses pharmacologiques du pacap, un peptide prometteur pour le traitement de la maladie de Parkinson, M\u00e9moire 2017. Qu\u00e9bec, Universit\u00e9 du Qu\u00e9bec, Institut national de la recherche scientifique, ma\u00eetrise en science, P17, 43, 65. (https:\/\/espace.inrs.ca\/id\/eprint\/7419\/1\/Lee-Gosselin-L-M-Decembre2017.pdf)"},{"issue":"1\u20132","key":"2366_CR75","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.pain.2007.03.012","volume":"130","author":"D Levy","year":"2007","unstructured":"Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM (2007) Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130(1\u20132):166\u2013176. https:\/\/doi.org\/10.1016\/j.pain.2007.03.012","journal-title":"Pain"},{"issue":"9","key":"2366_CR76","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.peptides.2007.05.002","volume":"28","author":"M Li","year":"2007","unstructured":"Li M, Maderdrut JL, Lertora JJ, Batuman V (2007) Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides 28(9):1891\u20131895. https:\/\/doi.org\/10.1016\/j.peptides.2007.05.002","journal-title":"Peptides"},{"key":"2366_CR77","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biopsych.2015.11.012","volume":"80","author":"Z Li","year":"2016","unstructured":"Li Z, Chen J, Xu Y, Yi Q, Ji W, Wang P, Shen J, Song Z, Wang M, Yang P, Wang Q, Feng G, Liu B, Sun W, Xu Q, Li B, He L, He G, Li W, Wen Z, Liu K, Huang F, Zhou J, Ji J, Li X, Shi Y (2016) Genome-wide analysis of the role of copy number variation in schizophrenia risk in Chinese. Biol Psychiatry 80:331\u2013337. https:\/\/doi.org\/10.1016\/j.biopsych.2015.11.012","journal-title":"Biol Psychiatry"},{"issue":"2","key":"2366_CR78","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/YPG.0b013e3282f60320","volume":"18","author":"FW Lohoff","year":"2008","unstructured":"Lohoff FW, Bloch PJ, Weller AE, Ferraro TN, Berrettini WH (2008) Association analysis of the pituitary adenylate cyclase-activating polypeptide (PACAP\/ADCYAP1) gene in bipolar disorder. Psychiatr Genet 18(2):53\u201358. https:\/\/doi.org\/10.1097\/YPG.0b013e3282f60320","journal-title":"Psychiatr Genet"},{"key":"2366_CR79","doi-asserted-by":"publisher","first-page":"8069","DOI":"10.3390\/ijms23158069","volume":"23","author":"J Lu","year":"2022","unstructured":"Lu J, Piper SJ, Zhao P, Miller LJ, Wootten D, Sexton PM (2022) Targeting VIP and PACAP receptor signaling: new insights into designing drugs for the PACAP subfamily of receptors. Int J Mol Sci 23:8069. https:\/\/doi.org\/10.3390\/ijms23158069","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2366_CR80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1242\/dmm.027185","volume":"10","author":"G Maasz","year":"2017","unstructured":"Maasz G, Zrinyi Z, Reglodi D, Petrovics D, Rivnyak A, Kiss T, Jungling A, Tamas A, Pirger Z (2017) Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models. Dis Model Mech 10(2):127\u2013139. https:\/\/doi.org\/10.1242\/dmm.027185","journal-title":"Dis Model Mech"},{"key":"2366_CR81","doi-asserted-by":"publisher","unstructured":"Martin TJ, Findlay DM, Moseley JM, Sexton PM (1998) Calcitonin. In: L V, Krane SM (eds) Metabolic bone disease and clinically related disorders, 3rd ed. Avioli, Academic Press, San Diego, USA, pp 95\u2013121. https:\/\/doi.org\/10.1016\/B978-012068700-8\/50005-0","DOI":"10.1016\/B978-012068700-8\/50005-0"},{"issue":"5","key":"2366_CR82","doi-asserted-by":"publisher","first-page":"bqad044","DOI":"10.1210\/endocr\/bqad044","volume":"164","author":"B Maunze","year":"2023","unstructured":"Maunze B, Choi S (2023) Hypothalamic PACAP\/PAC1R involvement in feeding and body weight regulation. Endocrinology 164(5):bqad044. https:\/\/doi.org\/10.1210\/endocr\/bqad044","journal-title":"Endocrinology"},{"issue":"3","key":"2366_CR83","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s12031-014-0309-4","volume":"54","author":"K Miyamoto","year":"2014","unstructured":"Miyamoto K, Tsumuraya T, Ohtaki H, Dohi K, Satoh K, Xu Z, Tanaka S, Murai N, Watanabe J, Sugiyama K, Aruga T, Shioda S (2014) PACAP38 suppresses cortical damage in mice with traumatic brain injury by enhancing antioxidant activity. J Mol Neurosci 54(3):370\u2013379. https:\/\/doi.org\/10.1007\/s12031-014-0309-4","journal-title":"J Mol Neurosci"},{"key":"2366_CR84","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/0006-291X(89)91757-9","volume":"161","author":"A Miyata","year":"1989","unstructured":"Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 161:567\u2013574. https:\/\/doi.org\/10.1016\/0006-291X(89)91757-9","journal-title":"Biochem Biophys Res Commun"},{"key":"2366_CR85","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/0006-291X(90)92140-U","volume":"170","author":"A Miyata","year":"1990","unstructured":"Miyata A, Jiang L, Dahl RD, Kitada C, Kubo K, Fujino M, Minamino N, Arimura A (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643\u2013648. https:\/\/doi.org\/10.1016\/0006-291X(90)92140-U","journal-title":"Biochem Biophys Res Commun"},{"key":"2366_CR86","doi-asserted-by":"publisher","unstructured":"Moody TW, Jensen RT (2016) PACAP and cancer. In: Reglodi D, Tamas A (eds) Pituitary adenylate cyclase activating polypeptide \u2014 PACAP, Current Topics in Neurotoxicity; Springer, Cham, Switzerland, Volume 11. https:\/\/doi.org\/10.1007\/978-3-319-35135-3_47","DOI":"10.1007\/978-3-319-35135-3_47"},{"issue":"10","key":"2366_CR87","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/s0196-9781(00)00309-0","volume":"21","author":"D Moreno","year":"2000","unstructured":"Moreno D, Gourlet P, De Neef P, Cnudde J, Waelbroeck M, Robberecht P (2000) Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor. Peptides 21(10):1543\u20131549. https:\/\/doi.org\/10.1016\/s0196-9781(00)00309-0","journal-title":"Peptides"},{"key":"2366_CR88","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3389\/fendo.2019.00227","volume":"10","author":"T Nakamachi","year":"2019","unstructured":"Nakamachi T, Tanigawa A, Konno N, Shioda S, Matsuda K (2019) Expression patterns of PACAP and PAC1R genes and anorexigenic action of PACAP1 and PACAP2 in zebrafish. Front Endocrinol 10:227. https:\/\/doi.org\/10.3389\/fendo.2019.00227","journal-title":"Front Endocrinol"},{"key":"2366_CR89","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1073\/pnas.071465398","volume":"98","author":"A Nicot","year":"2001","unstructured":"Nicot A, DiCicco-Bloom E (2001) Regulation of neuroblast mitosis is determined by PACAP receptor isoform expression. Proc Natl Acad Sci USA 98:4758\u20134763. https:\/\/doi.org\/10.1073\/pnas.071465398","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"2366_CR90","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/s0196-9781(02)00248-6","volume":"23","author":"N Nonaka","year":"2002","unstructured":"Nonaka N, Banks WA, Mizushima H, Shioda S, Morley JE (2002) Regional differences in PACAP transport across the blood-brain barrier in mice: a possible influence of strain, amyloid beta protein, and age. Peptides 23(12):2197\u20132202. https:\/\/doi.org\/10.1016\/s0196-9781(02)00248-6","journal-title":"Peptides"},{"issue":"1","key":"2366_CR91","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.expneurol.2004.09.013","volume":"191","author":"N Nonaka","year":"2005","unstructured":"Nonaka N, Shioda S, Banks WA (2005) Effect of lipopolysaccharide on the transport of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier. Exp Neurol 191(1):137\u2013144. https:\/\/doi.org\/10.1016\/j.expneurol.2004.09.013","journal-title":"Exp Neurol"},{"issue":"2","key":"2366_CR92","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.peptides.2012.05.021","volume":"36","author":"N Nonaka","year":"2012","unstructured":"Nonaka N, Farr SA, Nakamachi T, Morley JE, Nakamura M, Shioda S, Banks WA (2012) Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins. Peptides 36(2):168\u2013175. https:\/\/doi.org\/10.1016\/j.peptides.2012.05.021","journal-title":"Peptides"},{"key":"2366_CR93","unstructured":"Omeros-Corporation. Omeros identifies small molecules for class B GPCR (2013). Available online : https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-identifies-small-molecules-class-b-gpcr. Accessed 10 June 2023 at 20h12"},{"key":"2366_CR94","doi-asserted-by":"publisher","unstructured":"Pasupuleti MK (2024) Leveraging quantum chemistry simulations to optimize molecular dynamics in drug design. In:AI-driven drug design and molecular simulation. IJAIRI (3):134\u2013159. https:\/\/doi.org\/10.62311\/nesx\/48592","DOI":"10.62311\/nesx\/48592"},{"issue":"17","key":"2366_CR95","doi-asserted-by":"publisher","first-page":"13256","DOI":"10.3390\/ijms241713256","volume":"24","author":"E Patko","year":"2023","unstructured":"Patko E, Szabo E, Vaczy A, Molitor D, Tari E, Li L, Csutak A, Toth G, Reglodi D, Atlasz T (2023) Protective effects of pituitary adenylate-cyclase-activating polypeptide on retinal vasculature and molecular responses in a rat model of moderate glaucoma. Int J Mol Sci 24(17):13256. https:\/\/doi.org\/10.3390\/ijms241713256","journal-title":"Int J Mol Sci"},{"key":"2366_CR96","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fncel.2019.00114","volume":"13","author":"SH Pedersen","year":"2019","unstructured":"Pedersen SH, la Cour SH, Calloe K, Hauser F, Olesen J, Klaerke DA, Jansen-Olesen I (2019) PACAP-38 and PACAP(6\u201338) degranulate rat meningeal mast cells via the orphan MrgB3-receptor. Front Cell Neurosci 13:114. https:\/\/doi.org\/10.3389\/fncel.2019.00114","journal-title":"Front Cell Neurosci"},{"issue":"11","key":"2366_CR97","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1177\/0333102420937655","volume":"40","author":"L Pellesi","year":"2020","unstructured":"Pellesi L, Al-Karagholi MA, Chaudhry BA, Lopez CL, Snellman J, Hannibal J, Amin FM, Ashina M (2020) Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers. Cephalalgia 40(11):1212\u20131223. https:\/\/doi.org\/10.1177\/0333102420937655","journal-title":"Cephalalgia"},{"key":"2366_CR98","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","volume":"152","author":"U Rai","year":"2015","unstructured":"Rai U, Thrimawithana TR, Valery C, Young SA (2015) Therapeutic uses of somatostatin and its analogues: current view and potential applications. Pharmacol Ther 152:98\u2013110. https:\/\/doi.org\/10.1016\/j.pharmthera.2015.05.007","journal-title":"Pharmacol Ther"},{"key":"2366_CR99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.peptides.2015.01.009","volume":"66","author":"I Ramos-\u00c1lvarez","year":"2015","unstructured":"Ramos-\u00c1lvarez I, Mantey SA, Nakamura T, Nuche-Berenguer B, Moreno P, Moody TW, Maderdrut JL, Coy DH, Jensen RT (2015) A structure-function study of PACAP using conformationally restricted analogs: identification of PAC1 receptor-selective PACAP agonists. Peptides 66:26\u201342. https:\/\/doi.org\/10.1016\/j.peptides.2015.01.009","journal-title":"Peptides"},{"issue":"9","key":"2366_CR100","doi-asserted-by":"publisher","first-page":"3208","DOI":"10.1096\/fj.10-180133","volume":"25","author":"D Rat","year":"2011","unstructured":"Rat D, Schmitt U, Tippmann F, Dewachter I, Theunis C, Wieczerzak E, Postina R, van Leuven F, Fahrenholz F, Kojro E (2011) Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J 25(9):3208\u20133218. https:\/\/doi.org\/10.1096\/fj.10-180133","journal-title":"FASEB J"},{"issue":"6","key":"2366_CR101","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/01.str.31.6.1411","volume":"31","author":"D Reglodi","year":"2000","unstructured":"Reglodi D, Somogyvari-Vigh A, Vigh S, Kozicz T, Arimura A (2000) Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. Stroke 31(6):1411\u20131417. https:\/\/doi.org\/10.1161\/01.str.31.6.1411","journal-title":"Stroke"},{"issue":"33","key":"2366_CR102","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.2174\/1381612824666181112110934","volume":"24","author":"D Reglodi","year":"2018","unstructured":"Reglodi D, Atlasz T, Jungling A, Szabo E, Kovari P, Manavalan S, Tamas A (2018a) Alternative routes of administration of the neuroprotective pituitary adenylate cyclase activating polypeptide. Curr Pharm des 24(33):3892\u20133904. https:\/\/doi.org\/10.2174\/1381612824666181112110934","journal-title":"Curr Pharm des"},{"key":"2366_CR103","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.neuro.2018.03.010","volume":"66","author":"D Reglodi","year":"2018","unstructured":"Reglodi D, Tamas A, Jungling A, Vaczy A, Rivnyak A, Fulop BD, Szabo E, Lubics A, Atlasz T (2018b) Protective effects of pituitary adenylate cyclase activating polypeptide against neurotoxic agents. Neurotoxicology 66:185\u2013194. https:\/\/doi.org\/10.1016\/j.neuro.2018.03.010","journal-title":"Neurotoxicology"},{"issue":"7335","key":"2366_CR104","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature09856","volume":"470","author":"KJ Ressler","year":"2011","unstructured":"Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EB, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470(7335):492\u2013497. https:\/\/doi.org\/10.1038\/nature09856","journal-title":"Nature"},{"issue":"11","key":"2366_CR105","first-page":"3105","volume":"60","author":"JC Reubi","year":"2000","unstructured":"Reubi JC, L\u00e4derach U, Waser B, Gebbers JO, Robberecht P, Laissue JA (2000) Vasoactive intestinal peptide\/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60(11):3105\u20133112","journal-title":"Cancer Res"},{"key":"2366_CR106","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.peptides.2017.10.01","volume":"99","author":"EM Rhea","year":"2018","unstructured":"Rhea EM, Bullock KM, Banks WA (2018) Effect of controlled cortical impact on the passage of pituitary adenylate cyclase activating polypeptide (PACAP) across the blood-brain barrier. Peptides 99:8\u201313. https:\/\/doi.org\/10.1016\/j.peptides.2017.10.01","journal-title":"Peptides"},{"issue":"12","key":"2366_CR107","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.3390\/pharmaceutics15122661","volume":"15","author":"C Rigaut","year":"2023","unstructured":"Rigaut C, Deruyver L, Niesen M, Vander Ghinst M, Goole J, Lambert P, Haut B (2023) What are the key anatomical features for the success of nose-to-brain delivery? A study of powder deposition in 3d-printed nasal casts. Pharmaceutics 15(12):2661. https:\/\/doi.org\/10.3390\/pharmaceutics15122661","journal-title":"Pharmaceutics"},{"key":"2366_CR108","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/ijms19041020","volume":"19","author":"A Rivnyak","year":"2018","unstructured":"Rivnyak A, Kiss P, Tamas A, Balogh D, Reglodi D (2018) Review on PACAP-induced transcriptomic and proteomic changes in neuronal development and repair. Int J Mol Sci 19:1020. https:\/\/doi.org\/10.3390\/ijms19041020","journal-title":"Int J Mol Sci"},{"key":"2366_CR109","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/00016346909157733","volume":"48","author":"G Ryd\u00e9n","year":"1969","unstructured":"Ryd\u00e9n G, Sj\u00f6holm I (1969) Half-life of oxytocin in blood of pregnant and non-pregnant woman. Acta Obstet Gynecol Scand 48:139\u2013140. https:\/\/doi.org\/10.3109\/00016346909157733","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"10","key":"2366_CR110","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","volume":"26","author":"E Samaridou","year":"2018","unstructured":"Samaridou E, Alonso MJ (2018) Nose-to-brain peptide delivery - the potential of nanotechnology. Bioorg Med Chem 26(10):2888\u20132905. https:\/\/doi.org\/10.1016\/j.bmc.2017.11.001","journal-title":"Bioorg Med Chem"},{"key":"2366_CR111","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s12031-017-1025-7","volume":"68","author":"Z Sarszegi","year":"2019","unstructured":"Sarszegi Z, Szabo D, Gaszner B, Konyi A, Reglodi D, Nemeth J, Lelesz B, Polgar B, Jungling A, Tamas A (2019) Examination of pituitary adenylate cyclase-activating polypeptide (PACAP) as a potential biomarker in heart failure patients. J Mol Neurosci 68:368\u2013376. https:\/\/doi.org\/10.1007\/s12031-017-1025-7","journal-title":"J Mol Neurosci"},{"key":"2366_CR112","doi-asserted-by":"publisher","first-page":"12302","DOI":"10.1038\/s41598-023-39571-y","volume":"13","author":"S Sbei","year":"2023","unstructured":"Sbei S, Moncrief T, Limjunyawong N, Zeng Y, Green DP (2023) PACAP activates MRGPRX2 on meningeal mast cells to drive migraine-like pain. Sci Rep 13:12302. https:\/\/doi.org\/10.1038\/s41598-023-39571-y","journal-title":"Sci Rep"},{"issue":"595","key":"2366_CR113","doi-asserted-by":"publisher","first-page":"eaba7394","DOI":"10.1126\/scitranslmed.aba7394","volume":"13","author":"AW Schaler","year":"2021","unstructured":"Schaler AW, Runyan AM, Clelland CL, Sydney EJ, Fowler SL, Figueroa HY, Shioda S, Santa-Maria I, Duff KE, Myeku N (2021) PAC1 receptor-mediated clearance of tau in postsynaptic compartments attenuates tau pathology in mouse brain. Sci Transl Med 13(595):eaba7394. https:\/\/doi.org\/10.1126\/scitranslmed.aba7394","journal-title":"Sci Transl Med"},{"key":"2366_CR114","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/brain\/awn307","volume":"132","author":"HW Schytz","year":"2009","unstructured":"Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16\u201325. https:\/\/doi.org\/10.1093\/brain\/awn307","journal-title":"Brain"},{"key":"2366_CR115","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2353\/ajpath.2010.090941","volume":"177","author":"S Seeliger","year":"2010","unstructured":"Seeliger S, Buddenkotte J, Schmidt-Choudhury A, Rosignoli C, Shpacovitch V, von Arnim U, Metze D, Rukwied R, Schmelz M, Paus R, Voegel JJ, Schmidt WE, Steinhoff M (2010) Pituitary adenylate cyclase activating polypeptide: an important vascular regulator in human skin in vivo. Am J Pathol 177:2563\u20132575. https:\/\/doi.org\/10.2353\/ajpath.2010.090941","journal-title":"Am J Pathol"},{"key":"2366_CR116","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1210\/jcem-48-1-50","volume":"48","author":"M Sheppard","year":"1979","unstructured":"Sheppard M, Shapiro B, Pimstone B, Kronheim S, Berelowitz M, Gregory M (1979) Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48:50\u201353. https:\/\/doi.org\/10.1210\/jcem-48-1-50","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2366_CR117","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.3390\/ijms24044169","volume":"24","author":"J Shibato","year":"2023","unstructured":"Shibato J, Takenoya F, Yamashita M, Gupta R, Min CW, Kim ST, Kimura A, Takasaki I, Hori M, Shioda S, Rakwal R (2023) OMICS analyses unraveling related gene and protein-driven molecular mechanisms underlying PACAP 38-induced neurite outgrowth in PC12 cells. Int J Mol Sci 24(4):4169. https:\/\/doi.org\/10.3390\/ijms24044169","journal-title":"Int J Mol Sci"},{"key":"2366_CR118","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.bbrc.2022.09.079","volume":"631","author":"Y Shintani","year":"2022","unstructured":"Shintani Y, Yamano Y, Kuta M, Takeshita R, Takuma K, Okada T, Toyooka N, Takasaki I, Miyata A, Kurihara T, Hashimoto H, Hayata-Takano A (2022) Small-molecule non-peptide antagonists of the PACAP receptor attenuate acute restraint stress-induced anxiety-like behaviors in mice. Biochem Biophys Res Commun 631:146\u2013151. https:\/\/doi.org\/10.1016\/j.bbrc.2022.09.079","journal-title":"Biochem Biophys Res Commun"},{"key":"2366_CR119","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.peptides.2015.08.006","volume":"72","author":"S Shioda","year":"2015","unstructured":"Shioda S, Nakamachi T (2015) PACAP as a neuroprotective factor in ischemic neuronal injuries. Peptides 72:202\u2013207. https:\/\/doi.org\/10.1016\/j.peptides.2015.08.006","journal-title":"Peptides"},{"issue":"1\u20133","key":"2366_CR120","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12031-008-9107-1","volume":"36","author":"S Shioda","year":"2008","unstructured":"Shioda S, Vaudry H, May V, Braas K, Reglodi D, Gozes I (2008) In memory of our teacher. Dr Akira Arimura J Mol Neurosci 36(1\u20133):3\u20137. https:\/\/doi.org\/10.1007\/s12031-008-9107-1","journal-title":"Dr Akira Arimura J Mol Neurosci"},{"key":"2366_CR121","doi-asserted-by":"publisher","first-page":"797541","DOI":"10.3389\/fphar.2021.797541","volume":"12","author":"I Sol\u00e9s-Tarr\u00e9s","year":"2022","unstructured":"Sol\u00e9s-Tarr\u00e9s I, Cabezas-Llobet N, Lefranc B, Leprince J, Alberch J, Vaudry D, Xifr\u00f3 X (2022) a Pituitary adenylate cyclase-activating polypeptide (PACAP) protects striatal cells and improves motor function in Huntington\u2019s disease models: role of PAC1 receptor. Front Pharmacol 12:797541. https:\/\/doi.org\/10.3389\/fphar.2021.797541","journal-title":"Front Pharmacol"},{"key":"2366_CR122","unstructured":"Sol\u00e9s-Tarr\u00e9s I, Alberch IJ, Vaudry D, Xifro X (2022) b Synthetic analogues of pituitary adenylate cyclase-activating polypeptide (PACAP) improve motor deficits in R6\/1 mouse model of Huntington\u2019s disease. VI Conference of Pre-Doctoral Researchers Abstract Book edited by Gerardo Boto & Laia Vicens, Volume VI, P67. University of Girona. Spain. https:\/\/dugi-doc.udg.edu\/bitstream\/handle\/10256\/22435\/Book_of_Abstracts_JoDoc2022.pdf?sequence=1#page=69. Consuted 05\/06\/2023 at 23h25."},{"issue":"1\u20133","key":"2366_CR123","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0167-0115(00)00123-3","volume":"91","author":"A Somogyv\u00e1ri-Vigh","year":"2000","unstructured":"Somogyv\u00e1ri-Vigh A, Pan W, Regl\u00f6di D, Kastin AJ, Arimura A (2000) Effect of middle cerebral artery occlusion on the passage of pituitary adenylate cyclase activating polypeptide across the blood-brain barrier in the rat. Regul Pept 91(1\u20133):89\u201395. https:\/\/doi.org\/10.1016\/s0167-0115(00)00123-3","journal-title":"Regul Pept"},{"key":"2366_CR124","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/NDT.S4176","volume":"5","author":"DR Staines","year":"2009","unstructured":"Staines DR, Brenu EW, Marshall-Gradisnik S (2009) Postulated vasoactive neuropeptide immunopathology affecting the blood-brain\/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: a role for phosphodiesterase inhibitors in treatment? Neuropsychiatr Dis Treat 5:81\u201389. https:\/\/doi.org\/10.2147\/NDT.S4176","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"2366_CR125","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0304-3940(92)90288-i","volume":"137","author":"K Suda","year":"1992","unstructured":"Suda K, Smith DM, Ghatei MA, Bloom SR (1992) Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain. Neurosci Lett 137(1):19\u201323. https:\/\/doi.org\/10.1016\/0304-3940(92)90288-i","journal-title":"Neurosci Lett"},{"key":"2366_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.117.245415","volume":"365","author":"I Takasaki","year":"2018","unstructured":"Takasaki I, Watanabe A, Yokai M, Watanabe Y, Hayakawa D, Nagashima R, Fukuchi M, Okada T, Toyooka N, Miyata A, Gouda H, Kurihara T (2018) In silico screening identified novel small-molecule antagonists of PAC1 receptor. J Pharmacol Exp Ther 365:1\u20138. https:\/\/doi.org\/10.1124\/jpet.117.245415","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"2366_CR127","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jphs.2018.11.011","volume":"139","author":"I Takasaki","year":"2019","unstructured":"Takasaki I, Nakamura K, Shimodaira A, Watanabe A, Du Nguyen H, Okada T, Toyooka N, Miyata A, Kurihara T (2019) The novel small-molecule antagonist of PAC1 receptor attenuates formalin-induced inflammatory pain behaviors in mice. J Pharmacol Sci 139(2):129\u2013132. https:\/\/doi.org\/10.1016\/j.jphs.2018.11.011","journal-title":"J Pharmacol Sci"},{"issue":"4","key":"2366_CR128","doi-asserted-by":"publisher","first-page":"e00065","DOI":"10.1042\/AN20110024","volume":"3","author":"YV Tan","year":"2011","unstructured":"Tan YV, Waschek JA (2011) Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro 3(4):e00065. https:\/\/doi.org\/10.1042\/AN20110024","journal-title":"ASN Neuro"},{"issue":"7339","key":"2366_CR129","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature09884","volume":"471","author":"V Vacic","year":"2011","unstructured":"Vacic V, McCarthy S, Malhotra D, Murray F, Chou HH, Peoples A, Makarov V, Yoon S, Bhandari A, Corominas R, Iakoucheva LM, Krastoshevsky O, Krause V, Larach-Walters V, Welsh DK, Craig D, Kelsoe JR, Gershon ES, Leal SM, Dell Aquila M, Morris DW, Gill M, Corvin A, Insel PA, McClellan J, King MC, Karayiorgou M, Levy DL, DeLisi LE, Sebat J (2011) Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature 471(7339):499\u2013503. https:\/\/doi.org\/10.1038\/nature09884","journal-title":"Nature"},{"issue":"1\u20133","key":"2366_CR130","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.regpep.2007.06.006","volume":"144","author":"A Valdehita","year":"2007","unstructured":"Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM (2007) Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul Pept 144(1\u20133):101\u2013108. https:\/\/doi.org\/10.1016\/j.regpep.2007.06.006","journal-title":"Regul Pept"},{"issue":"1","key":"2366_CR131","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mce.2008.11.024","volume":"302","author":"A Valdehita","year":"2009","unstructured":"Valdehita A, Bajo AM, Schally AV, Varga JL, Carmena MJ, Prieto JC (2009) Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol Cell Endocrinol 302(1):41\u201348. https:\/\/doi.org\/10.1016\/j.mce.2008.11.024","journal-title":"Mol Cell Endocrinol"},{"key":"2366_CR132","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/s0306-4522(97)00545-9","volume":"84","author":"D Vaudry","year":"1998","unstructured":"Vaudry D, Gonzalez BJ, Basille M, Anouar Y, Fournier A, Vaudry H (1998) Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway. Neuroscience 84:801\u2013812. https:\/\/doi.org\/10.1016\/s0306-4522(97)00545-9","journal-title":"Neuroscience"},{"key":"2366_CR133","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0031-6997(24)01449-2","volume":"52","author":"D Vaudry","year":"2000","unstructured":"Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269\u2013324","journal-title":"Pharmacol Rev"},{"key":"2366_CR134","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1124\/pr.109.001370","volume":"61","author":"D Vaudry","year":"2009","unstructured":"Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61:283\u2013357","journal-title":"Pharmacol Rev"},{"key":"2366_CR135","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13195-023-01334-2","volume":"15","author":"Q Wang","year":"2023","unstructured":"Wang Q, Wang Y, Li S, Shi J (2023) PACAP\u2013Sirtuin3 alleviates cognitive impairment through autophagy in Alzheimer\u2019s disease. Alz Res Therapy 15:184. https:\/\/doi.org\/10.1186\/s13195-023-01334-2","journal-title":"Alz Res Therapy"},{"issue":"15","key":"2366_CR136","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1167\/iovs.16-20630","volume":"57","author":"D Werling","year":"2016","unstructured":"Werling D, Reglodi D, Banks WA, Salameh TS, Kovacs K, Kvarik T, Vaczy A, Kovacs L, Mayer F, Danyadi B, Lokos E, Tamas A, Toth G, Biro Z, Atlasz T (2016) Ocular delivery of PACAP1-27 protects the retina from ischemic damage in rodents. Invest Ophthalmol vis Sci 57(15):6683\u20136691. https:\/\/doi.org\/10.1167\/iovs.16-20630","journal-title":"Invest Ophthalmol vis Sci"},{"key":"2366_CR137","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.3390\/IJMS20164052","volume":"20","author":"M Wici\u0144ski","year":"2019","unstructured":"Wici\u0144ski M, G\u00f3rski K, Walczak M, W\u00f3dkiewicz E, S\u0142upski M, Pawlak-Osi\u0144ska K, Malinowski B (2019) Neuroprotective properties of linagliptin: focus on biochemical mechanisms in cerebral ischemia, vascular dysfunction and certain neurodegenerative diseases. Int J Mol Sci 20:4052. https:\/\/doi.org\/10.3390\/IJMS20164052","journal-title":"Int J Mol Sci"},{"key":"2366_CR138","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1124\/jpet.493.130936","volume":"389","author":"W Xu","year":"2024","unstructured":"Xu W, Keith A, Ye W, Hu X, Deganutti G, Henderson M, Sexton P, Eiden L (2024) PACAP(6\u201338) deletants as peptide-based PACAP antagonists. J Pharmacol Exp Ther 389:493. https:\/\/doi.org\/10.1124\/jpet.493.130936","journal-title":"J Pharmacol Exp Ther"},{"key":"2366_CR139","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.expneurol.2013.01.015","volume":"247","author":"D Yang","year":"2013","unstructured":"Yang D, Sun YY, Lin X, Baumann JM, Dunn RS, Lindquist DM, Kuan CY (2013) Intranasal delivery of cell-penetrating anti-NF-\u03baB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury. Exp Neurol 247:447\u2013455. https:\/\/doi.org\/10.1016\/j.expneurol.2013.01.015","journal-title":"Exp Neurol"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-025-02366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12031-025-02366-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-025-02366-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:19:51Z","timestamp":1759763991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12031-025-02366-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":139,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1007\/s12031-025-02366-z","relation":{},"ISSN":["1559-1166"],"issn-type":[{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"80"}}